Skip to main content

About NED

“Research is to see what everybody else has seen, and think what nobody has thought.”

-Dr. Albert Szent-Györgyi, MD, PhD de Nagyrápolt – 1937 winner of the Nobel Prize in Physiology or Medicine

Through the leadership and drive of Rebecca Lambert, NED Biosystems’ founder and CEO, and NED’s expert team, NED’s focus is to use its novel systems methodology to foster revolutionary solutions.

Our Mission and Principles

Our mission is to provide uncommon therapies. NED’s goal is that patients may achieve and sustain “No Evidence of Disease.” We define uncommon therapies as those that lack customary toxicity and side effects and allow patients to live life fully.

As a Delaware Public Benefit Corporation, NED is committed to developing treatments suitable for patients globally, including those patients who today lack access to care.

We are driven by our guiding principles:

  • Addressing what patients and families need and want
  • Integrity in everything we do
  • A systems translational approach supported by decades of research
  • Respect for the body’s innate ability to re-learn health
  • A passion for challenging what most assume “cannot be done”

Our Team

Core Management and Key Advisors

Scientific Advisory Board

Systems Champions

Sui Huang, MD, PhD – World- renowned systems biology and cancer stem cell expert. Professor, Institute for Systems Biology (ISB); Previously faculty at University of Calgary Institute of Biocomplexity and Informatics; Harvard Medical School Children’s Hospital. Education: University of Zurich, MD and postdoctoral fellow Folkman Labs, Boston First recipient of PhD Program for Physicians Award, PhD in molecular biology and physical chemistry.

Observational NED-170 Patients and Family Members

Susan Powell, PhD – (Clinical Psychologist). Observational NED-170 stage IV ER+PR+/HER2- breast cancer patient with multiple bony metastases to spine, ribs and pelvis with 6-12 month prognosis. Began NED-170, and at 4 months a PET scan confirmed a rare complete response. She remains on NED-170 and at over six years is still NED.

Mylene Huynh, MD, MPH – (Board certified Family Practice and Preventative Medicine Physician, Founder of TruPoint Health (prevent and reverse chronic diseases), Preventative Medicine and Biometrics at Uniformed Services University, Colonel (retired) US Air Force). Daughter of observational NED-170 stage III lunch cancer patient; surviving sister of observational NED-170 stage IV neuroendocrine thymus cancer. Mother now cancer free on NED-170 along with a kinase inhibitor without surgery, chemotherapy, or radiation.

Garry Powell, PhD – (Clinical Psychologist). Spouse of Susan Powell, observational NED-170 stage IV breast cancer patient who is now NED.

Paul Seymour, PhD – (Organizational Psychologist). Surviving spouse of observational NED-170 stage IV ovarian cancer patient.

Additional Champions of NED

Mitchell D. Achee, MD – (Board Certified Diagnostic Radiologist). Used systems approach treatment for his own stage IV leiomyosarcoma (LMS) and is now NED.

Stephen J. Bigelsen, MD – (Board Certified Allergy, Asthma, and Immunology Specialist). Used systems approach to eliminate his own stage IV pancreatic cancer and is now NED.

Robyn Thomson, MS, CCC-SLP – Surviving spouse of LTC Todd Thomson, US Army, lost to rare Stage 3c colon cancer due to Burn Pit Exposure.

Board of Directors

Strategic Advisors

Christine Davis
Caitlin Donohue
Jean Hamilton
Debra McDowell
Gale Pollock, CRNA, FACHE, FAAN, Maj. Gen. (Ret)
Randy Slack
John Warden, III, Col. (Ret)
Diane Whitty

Lead Investors

First Round Capital – Series A Lead Investor
Benjamin H. Griswold, IV – Series B Lead Investor

The Journey Begins

NED Biosystems evolved from an urgent research project directed by NED’s founder Rebecca Lambert, to extend survival for her sister Renée who was diagnosed in 2001 with a rare and deadly sarcoma, Leiomyosarcoma (LMS).  LMS strikes less than .25% of all cancer patients. There were no viable LMS treatment options available, and Renee’s prognosis was just 6-12 months.

Rebecca convened 18 internationally recognized oncology researchers to design and pursue a new treatment approach, using a non-toxic, evidence-based combination. Harvard’s Dr. Judah Folkman, a pioneer in “angiogenesis” (new blood vessel formation research) became her mentor. The initial systems protocol that was developed allowed Renee to live nine years with quality of life and without the toxicity and side effects customary with most cancer treatments.

To be considered for inclusion in the protocol, an agent had to be well-documented in humans as efficacious at a dose lacking toxicity and side effects. 

The original protocol was revised for a second patient to incorporate evidence-based agents well-documented to affect pancreatic cancer targets, including cancer stem cells (CSCs). This adjustment for the revised protocol, in retrospect, was a major one. Pancreatic cancer is as deadly as it is because of cancer stem cells (CSCs) and their pathways.

Today, NED’s refined patented treatment, NED-170, has allowed the first 27 observational patients (most heavily pre-treated, late-stage IV) extended survival with some achieving and sustaining no evidence of disease (“NED”).

This systems approach has also been rapidly applied by a team of scientists to the development of NED’s treatment approach for infectious disease, NED-260.

In 2023, systems biology pioneer Leroy Hood, MD, PhD, with whom NED is formally collaborating, confirmed NED has the only two systems treatments in development for cancer and infectious disease. A systems approach is designed to affect how a disease’s multiple systems (or processes) interact with each other. NED’s treatments comprehensively target the critical pathways that drive disease.

True to the initial filter established so many years ago for Renee, NED’s treatments combine only those agents that are documented to be effective against the most critical disease-driving targets at safe doses.

Close Menu
    Rebecca Lambert
    Founder, CEO, and Executive Chair

    Rebecca Lambert, NED’s Founder and CEO, has over 40 years of experience designing and executing strategies to solve complex issues in business, government, political and financial entities. For the last two decades, Ms. Lambert has led the development of NED’s novel systems treatments for complex disease.

    Ms. Lambert has two patents issued and one pending. The issued patent is for the composition of matter and method of use of a systems cancer treatment. A second patent is for angiogenic regulators and their use in disease diagnosis and treatment. The third patent pending is for the prophylaxis and treatment of upper respiratory viral infections.

    Ms. Lambert’s approach to disease has attracted systems pioneer, Leroy Hood, MD, PhD, (inventor of the DNA synthesizer, enabling technology for the human genome project) who has asked if NED‘s cancer treatment may be used in a large study he plans to show how cancer’s onset may be reversed. NED is collaborating with Dr. Hood and his Institute for Systems Biology in NED’s cancer clinical trial.

    Ms. Lambert’s systems treatment for cancer is unique, prioritizing the most significant drivers of the major processes that advance late-stage cancers (stages II-IV). This treatment combines evidence-based agents already documented as efficacious against key targets at safe non-toxic doses. Her compelling advocacy work with heavily pre-treated late stage IV “observational” cancer patients has been reported to the FDA.

    Lambert’s second oral systems protocol is for respiratory viruses (those known and not yet known) and has the attributes of a “universal” treatment to help better prepare for the next pandemic.

    Prior to founding NED, Ms. Lambert raised over $1B of client funds for Shaker Investments. Previously, she had founded a company that utilized groundbreaking telecommunications technologies to deploy the first compressed digital satellite delivery of multiple TV channels to 40% of U.S. hospitals. She also founded a company to upgrade FM radio properties by moving them into top 100 radio markets.

    Her Federal Government experience includes senior positions in the U.S. House, U.S. Senate, and the Reagan Administration. While Associate Deputy Secretary for the U.S. Department of Commerce during the Reagan Administration, she initiated the Federal Government’s first use of a “Memorandum of Understanding” (MOU) to secure $3B of contracts for U.S. companies to build Brazilian hydro projects. Ms. Lambert also served as Deputy Assistant Secretary of the U.S. Department of Energy. At the Senate, she served as chief of staff for U.S. Senator Malcolm Wallop, and for the Republican Senatorial Committee, Ted Stevens, Chairman.

    Early in her career, Ms. Lambert managed strategy for numerous statewide political campaigns including Senator Malcolm Wallop’s upset victory for the U.S. Senate. She was one of the first non-lawyers to associate with a major Washington, DC law firm, representing Wiley Rein & Fielding clients before the U.S. Congress, White House and other U.S. Departments and Agencies.

    While living in New York City, Ms. Lambert served as the President of Bellevue Hospital’s Bellevue Association Board. During her tenure this organization was revitalized to garner support of Bellevue’s “Heroes Behind the Headlines”– the clinicians, nurses, and allied healthcare workers who routinely care for New York’s police and firefighters, as well as the homeless.

    Ms. Lambert has a BA in political science from Simmons College, and she graduated from Harvard Business School’s Advanced Management Program.

    Timothy Brauns, MBA
    Corporate Development and Operations Advisor

    Timothy Brauns is an independent biotech consultant and the Technology Development Advisor for the Vaccine and Immunotherapy Center at the Massachusetts General Hospital. He has 30 years of operational management experience in healthcare and life sciences at both academic organizations and private companies including executive management positions at multiple biotech and medtech companies. During his career, he has developed specializations in strategic planning, strategic marketing, and the planning and execution of complex, inter-institutional technology development projects under accelerated development timelines. Mr. Brauns is an expert in sponsored program development and management, having helped small businesses and large institutions to secure and manage over $150 million in Federal and private R&D awards. He holds a master’s degree in business administration from Suffolk University in Boston.

    Michael Mansour, MD, PhD
    Chief Medical Advisor - Infectious Disease

    Assistant Professor of Medicine at Harvard Medical School
    Affiliation:
    Transplant Infectious Diseases and Immunocompromised Host Service
    Division of Infectious Diseases
    Department of Medicine
    Massachusetts General Hospital
    Boston, Massachusetts

    Michael Mansour is a physician-scientist who started his research career in the biotech sector and graduated with MD/PhD dual degrees from Boston University School of Medicine with a research concentration in immune responses against invading pathogens. He completed his medical residency at the Massachusetts General Hospital (MGH) in Boston, MA where he also served as a Chief resident, before completing the Harvard combined Infectious Diseases training program at MGH and the Brigham and Women’s Hospital. Dr. Mansour joined the MGH ID faculty in 2014, and now attends on the clinical Transplant Infectious Diseases and Immunocompromised Host Service, where he cares for solid and stem cell transplant recipients and those individuals with weakened immunity. Dr. Mansour is an investigator overseeing a RO1-funded laboratory with a focus on innate immune responses to infectious pathogens. He also directs several COVID-19 clinical trials testing novel treatments for coronavirus. In addition, he sits on several committees for the development of treatment guidelines for patients with COVID-
    19 infection.

    Carol Greve-Philips
    VP, Corporate Development

    Carol Greve-Philips is a senior business development executive with wide experience across different types of transactions, therapeutic modalities, corporate organizations and geographies. She has planned and executed licenses with academic institutions and private companies, developed partnerships and collaborations, and engaged in as both a buyer and a seller.

    As a senior executive in Corporate Development at Genzyme she was responsible for the business development activities of the flagship Rare Disease business, licensing new products for the portfolio of the business. She later joined Spark Therapeutics during its first three years as Head of Corporate Development and Strategy, completing transactions with Pfizer, Genable LLC, the University of Massachusetts Medical School, and Oklahoma Medical Research Foundation among others. Consulting to both Quad Technologies and Abfero Pharmaceuticals Carol was the business development architect behind the sale of both companies to BioTechne and Pharmacosmos, respectively. With more than 40 years across the biotech and pharmaceutical industries Carol is an experienced problem solver who enables agreement between motivated partners.

    Sue Stewart, JD, LLM
    Senior Regulatory Officer

    Susan Stewart has served as Kaleido’s Senior Vice President, Regulatory Affairs & Quality since April 2018. Ms. Stewart has worked for more than 28 years in biopharmaceutical regulatory affairs, with significant experience devising innovative strategies for novel therapeutics, overseeing regulatory submissions at various stages of product development and leading interactions with global health authorities. In addition to being an independent regulatory consultant for several years, she was senior vice president of regulatory affairs, quality, and compliance at Tokai Pharmaceuticals and vice president, regulatory affairs at Transmolecular. She also spent 13 years at Genzyme Corporation in regulatory and compliance roles, including serving as vice president, regulatory affairs after beginning her career with Abbott Laboratories.  She received her LL.M from Maurice A Dean School of Law at Hofstra University, her J.D. from Concord Law School at Purdue University Global and her B.A. from the University of Massachusetts.  She is a Fellow of the Regulatory Affairs Professionals Society (RAPS), a Director of the Board, and holds Regulatory Affairs Certifications (RAC) for both the US and Europe.

     

    Beth Silverstein, MS, RAC
    Regulatory Advisor

    Beth has more than 25 years’ experience as a regulatory affairs professional, designing product development and regulatory strategies for pharmaceuticals, biologics, medical devices, and combination products and representing U.S. and international clients in FDA product approval efforts. Her broad expertise also includes the development of dietary supplements, and cosmetic ingredients. She has prepared or managed the preparation of INDs, NDAs, Annual Reports, Investigator Brochures, and Safety Reports for drug and combination products. She has prepared and successfully filed regulatory submissions for medical devices, including 510(k)s, IDEs for significant risk devices, and premarket approval PMA submissions for implantable devices. She has prepared several successful orphan drug designation requests and requests for accelerated approval. She is currently a Director of SciLucent, a firm providing regulatory and scientific consulting services to the biopharmaceutical industry. Beth has an M.S. in Zoology (Physiology) from The Ohio State University and a B.S. in Biology from Binghamton University. She maintains Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professional Society (RAPS).

     

    William E. Gannon, Jr MD
    Medical Director / Medical Monitor

    Dr. Gannon has 35+ years of industry experience including medical/pharmacovigilance monitoring, data analysis, clinical protocol and program development, as well as regulatory [NDA; BLA; ANDA; IND; IDE; PMA; 510K submissions].  Dr. Gannon has held positions in multinational Clinical Research Organizations, medical device, biotech and pharmaceutical firms. Dr. Gannon has worked in diverse therapeutic areas including respiratory, infectious disease, dermatology, oncology, neurology, cardiovascular, genitourinary, gastrointestinal, general medicine and allergy among others. Dr. Gannon has managed clinical trials and operations as well as the design of corporate and regulatory strategies, regulatory submissions and execution of Phase 1 through Phase 4 clinical trials in the U.S., Europe and Asia. He has a strong understanding of US, Canadian, EU and Japanese regulatory requirements. Dr. Gannon received his medical training and clinical work in family practice at Ross University, Case Western Reserve and George Washington University. In addition, Dr. Gannon has an MBA with a concentration in Health Services Administration from George Washington University.

    Michelle Nelken
    Clinical Operations

    Michelle Nelken has 25 years experience in the pharmaceutical and biotechnology industry managing early and late phase clinical studies.  She has spent the majority of her career developing clinical programs in rare indications for small biotechnology companies. Earlier in her career Michelle spent 4 years with Alexion (formerly Enobia) as the Director of Clinical Operations leading to the successful approval of Strensiq® for the treatment of hypophosphatasia an ultra-rare metabolic disorder.  Prior to this she spent 2 years at Genzyme working on enzyme replacement therapies for lysosomal storage disorders and diagnostic studies and contributed to the regulatory approvals of Myozyme® for treatment of Pompe disease and the OSOM® Trichomonas Rapid Test. Michelle started her career at Biogen managing nonclinical studies in psoriasis that led to the regulatory approval of Amevive®.  She earned her Bachelor of Science in Nutrition from the University of Maine.

    Abdellah Sentissi, PhD
    Senior CMC and Product Development


    Dr. Sentissi joined NED Biosystems as a CMC and Pharmaceutical Development consultant in January 2021. Dr. Sentissi brings more than 35 years of experience leading manufacturing and quality functions for biotechnology companies. During his career working with several companies as a consultant or as functional leader, Dr. Sentissi led several products through scale-up, registration and validation runs, facility validation and all related quality assurance and control functions. Dr. Sentissi earned his Pharmacy degree from the School of Medicine and Pharmacy-University Paul Sabatier, Toulouse, France and a Ph.D. in Biomedical Sciences from Northeastern University. He also holds multiple French National Certifications in Medical Pathology, Immunology, Hematology and Parasitology from the School of Medicine and Pharmacy-University Paul Sabatier and the School of Pharmacy of Montpellier, France.

    Susan Paulson, PhD
    Clinical Pharmacology Advisor

    Dr. Paulson has 30+ years of experience in the pharmaceutical and biotechnology industries as a Clinical Pharmacologist and nonclinical ADME Scientist. As a clinical pharmacology and ADME expert, she contributed to the submissions of numerous aNDAs, NDAs, 505(b)(2), and INDs. Dr. Paulson has expertise in both large and small molecules with extensive global experience throughout each phase of development.  She was a scientist in the departments of drug metabolism and clinical pharmacology at G. D. Searle. In addition, she was Director of Clinical Pharmacology at Abbott Laboratories with responsibilities for HUMIRA® and other targets of immunology and inflammatory disease. She has 7 patents and 49 publications.  Susan received a PhD in Pharmacology from Texas Tech Health Sciences Center. She has served on the IRB for Children’s Memorial Hospital, Chicago, Illinois.  Dr. Paulson is an adjunct faculty at Northwestern University Medical School and a member of AAPS.

    Lisa Beauregard, CPA
    Financial Advisor

    Lisa has over 30 years of consulting, direct industry and Big-4 experience in finance & accounting, financial operations effectiveness, and business process improvement. Her clients and leadership finance roles span a broad spectrum of industries, including Healthcare, Medical Device, Technology, Consumer Products and Professional Services. Most recently, Lisa has been supporting companies with technical accounting and financial reporting, IPO readiness and filings, and due diligence on carve out acquisitions and financings.

    Lisa’s initial career started with 17 years at PricewaterhouseCoopers, achieving partner in 11 years. As one of the initial team members of the PwC Middle Market Advisory services, Lisa provided auditing and consulting to companies, including early-stage start-ups which were seeking consecutive rounds of financing and going public, private and public middle market clients.

    Over the last 13 years, Lisa has been in private industry holding CFO/SVP roles, working with early-stage companies to guide all aspects of their finance function, including establishing accounting systems and processes to ensure the effectiveness of their organization’s controls, creating relevant metrics and associated analyses to provide more strategically valuable information to management.

    Lisa is a Certified Public Accountant and in process of completing her Chartered Member Accountant (expected completion September 2021) and began her career with Coopers & Lybrand, now PricewaterhouseCoopers,. Lisa graduated magna cum laude from Boston College with a degree in Accounting and Finance.

    Elinor Mullins
    Business Operations Director

    Elinor Mullins, first employee, has worked with NED Biosystems for over 10 years–seeking to transform the treatment of complex disease globally. As Director of Business Operations, she designs business strategies and manages implementation to achieve essential goals for performance, streamlines communications with key consultants, supports product development through data research, participates in grant-writing efforts and communications with government entities, conducts patent substantiation research, and oversees daily operations of the company, and provides direct support to the Founder.

    Prior to joining NED, Ms. Mullins sat on the community board for the Palliative and Supportive Care of Nantucket foundation in support of their annual fundraising drive. During college she marketed the launch of a women-focused clinic for a specialized group of sports and orthopedic surgeons.

    Ms. Mullins has a BA in Cellular Molecular Biology with a concentration in Pre-Health, and a Minor in Architectural Studies from Connecticut College. Since 2011 she has served as Regional Coordinator for CommuniTyler, a nonprofit foundation with over 30 international sites, with the mission to “better our communities while making friends”. She also volunteers with Cape Ann Challenger Hockey, a program that introduces children and teens with developmental disabilities to adaptive ice skating.

    Brian Leyland Jones, BSc, MB BS, PhD, FRACP, FRCPC
    Chair, Scientific Advisory Board - Oncology

    Brian Leyland-Jones, BSc (Ist class Hons), MB BS, PhD, FRACP, FRCPC is the Chief Medical Officer and Scientific Advisory Board Member for the National Foundation For Cancer Research (NFCR). He also serves as the Chief Medical Officer of OTraces and the N OF 1 Mission, collectively devoted to the implementation of prevention and cure of malignancy globally.  He sits on several national and international boards including the Asian Foundation for Cancer Research (AFCR), Non-Pareil, and is Director Emeritus for the WIN Consortium.

    Dr.  Leyland-Jones holds biochemistry, medical, and doctoral degrees from the University of London. Following residency training at Hammersmith, Brompton, St. Bartholomew’s and London hospitals, he completed a clinical pharmacology fellowship at Cornell University and a medical oncology fellowship at Memorial Sloan-Kettering Cancer Center. He then joined the academic staff at Memorial Sloan-Kettering Cancer Center and New York Hospitals with a special research interest in Early Phase clinical, clinical pharmacological and biomarker evaluation of many anticancer compounds, including the platinums and anthracycline analogs in use today. In 1983, he moved to the National Cancer Institute (NCI) to head the Developmental Chemotherapy section. During his time with the NCI, he was responsible for the overall development of approximately 70 anti-cancer compounds in various stages of transition from in-vitro screening to Phase III clinical trials, including overseeing the early development of paclitaxel in Phase 1 and 2 trials. From 1990 to 2000, he served as founding chair of Oncology and director of the McGill University Comprehensive Cancer Centre. He recruited and built a broad multifaceted cancer centre, including a robust cross-hospital clinical trials enterprise, with deep clinical pharmacologic and biomarker support. Dr. Leyland-Jones continued as the Minda de Gunzberg Chair in Oncology and professor of medicine at McGill University in Montreal, Canada for 7 additional years, focusing on the development and biomarker strategies of several of the new targeted oncologic agents. Dr. Leyland-Jones is the recipient of the McGill University 2021 Lifetime Achievement Award.

    He joined Emory University in 2007. As Director of the Winship Cancer Centre and Associate Vice-President of Health Sciences, Dr. Leyland-Jones led the Centre to obtain National Cancer Institute Cancer Centre Designation, the first in the State of Georgia, and for the first time in 30 years. Dr. Leyland-Jones was instrumental in building the Genomics Medicine Program at the Avera Cancer Institute in Sioux Falls, SD where he was the Vice President of Molecular and Experimental Medicine from 2014-2019. Dr. Leyland-Jones’ principal academic contributions have been in the fields of anticancer therapy development, the pharmacodynamics, pharmacokinetics, and pharmacogenetics of oncological clinical trials, the translation of preclinical models into the clinic, biomarker endpoints in Phase I/II clinical trials, and screening and mechanistic studies of novel targeted and chemotherapeutic anticancer agents.

    Dr. Leyland-Jones is the recipient of numerous research grants, and has served as principal, co-principal and co-investigator on more than 100 clinical studies. He has authored and co-authored more than 210 peer-reviewed articles and book contributions, 25 books and book chapters, 425 abstracts and 35 patents.  He has a robust speaking and private consulting practice that takes him all over the world.

     

    Geoffrey Ling, MD, PhD, Col. (Ret.)
    Board of Directors, Scientific Advisory Board

    Dr. Geoffrey Ling is an internationally recognized innovation leader. Dr. Ling is co-founder at On Demand Pharmaceuticals – developing advanced, miniaturized, and automated pharmaceutical manufacturing systems that create from precursors to final formulated drugs. He is Co-Leader of The BrainHealth Project – an initiative to double human brain performance in the next 10 years. He also serves as a Professor of Neurology and is an Attending Neurocritical Care physician at Johns Hopkins University and Hospital and the Uniformed Services University of the Health Science (USUHS). Dr. Ling previously served as the Founding Director of the Biological Technologies Office at the Defense Advanced Research Projects Agency (DARPA) and also Assistant Director for Medical Innovation of the Science Division in President Obama’s White House Office of Science and Technology Policy (OSTP).  He is a retired U.S. Army colonel, who served for 27 years during which time he was deployed to Iraq and Afghanistan.

    Dr. Ling’s medical degree is from Georgetown University and his doctorate in Pharmacology is from Cornell University. He was a postdoctoral research fellow at Memorial Sloan Kettering Cancer Center. His neurology residency was done at Walter Reed Army Medical Center and his Neuro Critical Care fellowship at Johns Hopkins.  He has published over 200 peer-reviewed articles, book chapters and reviews.  He is a member of the honor societies of Alpha Omega Alpha, Sigma Xi and Military Medical Order of Merit. He is a fellow of the American Neurological Association, American Academy of Neurology and Neurocritical Care Society. He is a member of the Society for Critical Care Medicine, American Society of Pharmacology and Experimental Therapeutics and AMSUS (the Society of Federal Health Professionals).

    Gail M. Fennell, MD
    Scientific Advisor

    Dr. Fennell is an award-winning primary care physician leader, affiliated with Greenwich (CT) Hospital -Yale New Haven Health System. She has served as the managing partner of a multi-specialty physician practice, and has had various leadership positions with Stamford (CT) Hospital [New York Presbyterian Health Care Network]. She is an outstanding coordinator of medical services for her patients and is considered a “go-to resource” by her patients and peers for her diagnostic and treatment problem-solving. She brings expertise in internal medicine, preventative health and wellness. Dr. Fennell consistently receives “Top Doctor” awards, including NY Magazine-Best Doctor and exceeds benchmarks for quality and patient satisfaction. She remains vigilant on innovation and practice enhancements and is an outstanding communicator and strategist in the medical field. Dr. Fennell is a graduate of the University of Connecticut School of Medicine.

    Edward Garmey, MD
    Scientific Advisor

    Edward Garmey, M.D. is an oncology drug development consultant.  Dr. Garmey was formerly Chief Medical Officer and Senior Vice President at Cerulean Pharma, Inc., a clinical-stage oncology company based in Waltham, MA focused on the design and development of nanopharmaceutical-drug-conjugates differentially directed to cancer cells. Under his tenure at Cerulean, the company completed a successful IPO (NASDAQ:CERU) in April, 2014, and its clinical group, while increasing in size from one to 12 employees including three oncologist M.D.s, launched eight clinical trials and brought its second experimental drug into the clinic. Prior to being appointed to this role in 2011, Dr. Garmey served between 2008 and 2011 as Vice President for Clinical Development at ArQule, Inc., a publicly-traded cancer-focused biotechnology company located in Woburn, MA., where he developed and oversaw multiple international clinical trials of its lead product, ARQ 197 (tivantinib). Dr. Garmey additionally served there as a clinical development liaison with external development partners and assisted in the planning and execution of a license, co-development and co-commercialization agreement for the development of ARQ 197 in the United States and Europe. Prior to arriving at ArQule, Dr. Garmey was Medical Director at GPC Biotech in Princeton, New Jersey, where he helped oversee multiple global clinical development studies.

    A pediatric hematologist-oncologist by training, Dr. Garmey is a graduate of Harvard and New York Universities and completed his medical training at the Mount Sinai Medical Center (N.Y.); the Children’s Hospital of Los Angeles; and the Memorial Sloan-Kettering Cancer Center (N.Y.). Dr. Garmey completed additional research fellowships at the National Institutes of Health (1998-99) and Botswana-Harvard Partnership for H.I.V. Research in Gaborone, Botswana (1999-2000) and he is a recipient of young investigators awards from the American Society of Hematology and the American Heart Association. Dr. Garmey has presented at numerous international conferences and is an author on over 50 peer-reviewed abstracts and manuscripts. In 2009, he was appointed as a medical consultant to the New York City Investment Fund’s $1.25 Million “BioAccelerate NYC Prize” for biomedical research. Additionally, in 2011, he was appointed to the scientific advisory board of the Harvard-MIT Broad Institute’s Cancer Vaccine Initiative. Dr. Garmey resides near Boston, Massachusetts, where he serves as an adjunct instructor at Harvard Medical School’s Therapeutics Graduate Program and additionally as a member of the Board of Overseers at the Beth Israel Deaconess Medical Center.

    Dudley R. Herschbach, PhD
    Scientific Advisor

    Frank B. Baird Jr. Professor Emerita of Science
    Harvard University, Cambridge, MA
    Nobel Prize Recipient in Chemistry, 1986

    Dr. Dudley Herschbach is the Frank B. Baird Jr. Professor of Science, Emeritus at Harvard University. Born in San Jose, California, he obtained a B.S. in Mathematics (1954) and M. S. in Chemistry (1955) at Stanford, followed by an A.M. degree in Physics (1956) and Ph.D. in Chemical Physics (1958). He joined the chemistry faculty at the University of California, Berkeley (1959), where he launched novel molecular beam experiments to probe reaction dynamics in single collisions. He returned to Harvard (1963), expanding the beam experiments and much else over the next four decades. He taught a wide range of courses, graduate and undergraduate, including freshman chemistry for 20 years, his most challenging assignment. After becoming emeritus (2003) he continued teaching a freshman seminar (up to 2011, titled: “Molecular Motors: Wizards of the Nanoworld”). He also enjoyed some visiting appointments, especially in physics at Texas A & M University (2005-2017).

    His efforts to enhance science education and public understanding centered for many years with the Society for Science and the Public, which publishes Science News and conducts the Science Talent Search and the International Science and Engineering Fair. He long-chaired the Hans Bethe Center for Arms Control and Nonproliferation, and is a Life member of Friends of Benjamin Franklin and of The Sierra Club.

    Honors include the Nobel Prize (1986), shared with Yuan Lee and John Polanyi.  Among others much appreciated are Honorary Life Member of the Association of Women Scientists (1998); and three prizes named for him: Harvard Chemistry Teaching Prize for Graduate Students; Harvard University Teacher/Scientist Lectureship; and a Molecular Dynamics Prize.

    Judith E. Karp, MD
    Scientific Advisor

    Professor Emerita of Oncology and Medicine
    The Johns Hopkins University School of Medicine, Baltimore, MD

    Dr. Judith Karp, MD is a Professor Emerita of Oncology and Medicine at Johns Hopkins University School of Medicine where she was Professor of oncology and Director of the Adult Leukemia Program in the Division of Hematologic Malignancies at The Sidney Kimmel Comprehensive Cancer Center, until 2013. Dr. Karp’s primary clinical interest is the experimental therapeutics of acute leukemias. She has authored 275 peer-reviewed articles and 35 book chapters, and edited 2 textbooks on acute leukemias, most recently ​an innovative textbook entitled “Acute Leukemia: An Illustrated Guide to Diagnosis and Treatment.” Dr. Karp maintains active involvement with former fellows and faculty in terms of clinical trials development, design and analysis, and serves on the central IRB for the National Cancer Institute and is Chairman of the DSMC for The Leukemia & Lymphoma Society Beat AML Umbrella Clinical Trial and for the Tolero Phase II Biomarker-Driven Study of the Cyclin Dependent Kinase Inhibitor Alvocidib. She has received the Dr. John J. Kenny and Spiral of Life Awards from the Leukemia Lymphoma Society.

     

    Robert S. Kerbel, PhD
    Scientific Advisor

    Professor, University of Toronto

    Senior Scientist, Sunnybrook Health Services Center

    Dr. Robert Kerbel received his PhD in immunology in 1972 from the Dept. of Immunology & Microbiology, Queen’s University, Kingston, Ontario, Canada, after which he undertook postdoctoral training in London at the Institute for Cancer Research in tumor immunology. He started his independent research program in 1975 studying tumor immunology and metastasis at Queen’s, and was appointed Director of the Cancer Biology Program in the Dept. of Pathology in 1981. In 1985 he was recruited as Director of Cancer Biology Research at Mt. Sinai Hospital, Toronto. He then moved to Sunnybrook Health Sciences Centre to assume the same position from 1991 until 2001.

    Dr. Kerbel held a Canada Research Chair in Tumor Biology, Angiogenesis & Antiangiogenic Therapy (2001-2015), and is a professor in the Dept. of Medical Biophysics at the University of Toronto, and Senior Scientist at the Sunnybrook Research Institute. His overall main research interest has been devising new cancer treatment strategies having improved efficacy and reduced toxicity for the treatment of metastatic disease. This culminated in his translational studies of combinatorial low-dose ‘metronomic’ chemotherapy with antiangiogenic drugs. Other major contributions include development of improved preclinical investigational therapeutic models in mice involving early stage or advanced metastatic disease, linking the fields of angiogenesis and oncogenes, uncovering mechanisms by which antiangiogenic drugs increase chemotherapy efficacy, and elucidating mechanisms of intrinsic or acquired antiangiogenic drug resistance. His current major research interests include assessment of ‘vessel co-option’ in tumors in response to antiangiogenic drugs, and combination therapy utilizing immune checkpoint inhibitors with VEGF (or ang2) targeting antiangiogenic drugs, using new mouse models for immune therapy his lab is developing.

    Dr. Kerbel has published 417 papers, given 862 invited lectures around the world. He is and has been an editorial board member of numerous international scientific journals. Currently these include Molecular Cancer Therapeutics, EMBO Molecular Medicine, and the International Journal of Cancer. Among the awards he has received include the 2004 Canadian Cancer Society Robert Noble Award for Excellence in Cancer Research, the Breast Cancer Research Award from the European Institute of Oncology in 2008, a Man of Distinction Honor by the Israel Cancer Research Fund in 2011, and the Colin Thomson Memorial Medal for achievements in cancer research from Worldwide Cancer Research (formerly known as the Association for International Cancer Research) in 2013. His research studies have been supported by numerous agencies including the National Institutes of Health, USA, the Canadian Cancer Society Research Institute, the Canadian Institutes of Health Research, the Canadian Breast Cancer Foundation, and Worldwide Cancer Research. He also collaborated extensively with industry and has consulted for over 20 pharmaceutical and biotech companies during the last 25 years.

     

    Razelle Kurzrock, MD
    Scientific Advisor

    Distinguished Professor of Medicine,
    Associate Director, Clinical Science,
    Director, Center for Personalized Cancer Therapy,
    Leader, Experimental Therapeutics,
    Director, Rare Tumor Clinic, University of California, San Diego, Moores Cancer Center

    Dr. Razelle Kurzrock is known for founding and building the largest Phase 1 clinical trials department in the nation/world while at the University of Texas M.D. Anderson Cancer Center. A central theme of that program was the precision medicine strategy, embodied in a protocol called PREDICT for Profile-related Evidence Determining Individualized Cancer Therapy.

    At University of California, San Diego Moores Cancer Center, Dr. Kurzrock’s charge is heading its newly established Center for Personalized Cancer Therapy. This center focuses on genomically-driven therapy as well as precision immunotherapy, especially in rare cancers. Dr. Kurzrock is a global leader in personalized medicine, bringing the first transcriptomic study to the clinic in an international setting spanning five countries (WINTHER), as well as the first study of individually customized combination therapy (IPREDICT) (both Nature Medicine, April 2019).

    Dr. Kurzrock received her MD degree from the University of Toronto, Canada.  She has >800 PubMed publications, an H-index of 117, has been named to the list of most highly cited scientists in the world and the 25 world leaders in precision medicine, and she has a uniquely strong record of competitive funding with more than 100 million dollars in lifetime funding.

    Importantly, Dr Kurzrock has a special interest in Rare Cancers, a large unmet need.  Dr. Kurzrock founded a Rare Tumor Clinic at UCSD and heads the Rare Cancers and Early Therapeutics Committee for the NCI cooperative group SWOG.  The effort that Dr. Kurzrock is most passionate about is changing the course of disease for patients with cancer.  Patients are at the heart of her work.

    Dr. Kurzrock has four children and three dogs and lives with her husband, Dr. Philip Cohen, a dermatologist, in San Diego, CA.

    Marsha A. Moses, PhD
    Scientific Advisor

    Dr. Marsha A. Moses is the Julia Dyckman Andrus Professor at Harvard Medical School and the Director of the Vascular Biology Program at Boston Children’s Hospital. She is internationally recognized for her significant contributions to our understanding of the biochemical and molecular mechanisms that underlie the regulation of tumor development and progression. Dr. Moses and her laboratory have discovered several inhibitors of these processes that function at both the transcriptional and translational level, some of which are being developed for potential clinical use in a variety of human diseases. Named a pioneer in the field of Biomarker Medicine by the Journal of the National Cancer Institute, she created a Proteomics Initiative at Boston Children’s Hospital, has utilized its resources, including an extensive human biorepository and has leveraged her significant expertise in proteomics, to discover and validate a number of novel, non-invasive biomarkers for a variety of human cancers and non-neoplastic diseases.  Several of these biomarkers are currently being used in clinical trials. Dr. Moses and her team have engineered novel, actively targeted, precision nanomedicines for the treatment of human cancers and their metastases. A number of these therapeutics and diagnostics are included in Dr. Moses’ significant patent portfolio composed of both US and foreign patents.
    Dr. Moses’ basic and translational work has been published in such journals as Science, The New England Journal of Medicine, Cell, PNAS and Nature Communications, among others. She received a Ph.D.in Biochemistry from Boston University and completed a National Institutes of Health postdoctoral fellowship at Boston Children’s Hospital and MIT in the laboratory of Dr. Robert Langer. Dr. Moses is the recipient of a number of NIH and foundation grants and numerous awards and honors. Most recently, she was the 2021 recipient of the American Association for Cancer Research (AACR)-Women in Cancer Research Charlotte Friend Lectureship. Dr. Moses has been recognized with both of Harvard Medical School’s mentoring awards, the A. Clifford Barger Mentoring Award and the Joseph B. Martin Dean’s Leadership Award for the Advancement of Women Faculty. Marsha has received the Excellence in Mentoring Award from the Postdoc Association of Boston Children’s Hospital and has also received their Award for Exceptional Mentorship. She has also received the Honorary Member Mentoring Award from the Association of Women Surgeons of the American College of Surgeons.
    Dr. Moses has been elected to the Institute of Medicine (National Academy of  Medicine) of the National Academies of the United States, the National Academy of Inventors, the American Institute for Medical and Biological Engineering, as a Fellow of the American Association for the Advancement of Science and was recently elected to the American Academy of Arts and Sciences.

    Michael Stebbins, PhD
    Scientific Advisor

    Michael Stebbins is the President of Science Advisors, a science and health consulting firm he founded in 2018. He served as the Assistant Director for Biotechnology in the Obama White House Office of Science and Technology Policy and is the principal driver of the creation of ARPA-H.

    While at the White House, Dr. Stebbins developed eight Executive Orders and other Federal directives addressing issues including the antibiotic resistance crisis, restoration of pollinator health, the purchasing of bio-based products, improving veterans’ mental health, increasing access to federally funded scientific research publications and data, evaluating and addressing the preferential purchasing of antibiotic free meats, reforming the regulatory system for biotechnology products, and improving the management of scientific collections. He was a leader in the White House on driving a case to the Supreme Court on the patenting of genes and was the White House staff lead on recommendations to the President on drug innovation and antibiotic resistance reports developed by the President’s Council of Advisors on Science and Technology.

    Dr. Stebbins served as a science advisor to the Obama and Biden Presidential campaigns and on the Obama White House Transition Team. He worked for U.S. Senator Harry Reid as the lead on embryonic stem cells that forced President Bush’s first veto. He is the former Vice President of Science and Technology for the Laura and John Arnold Foundation, and director of biology policy for the Federation of American Scientists. Before coming to Washington, he was a senior editor at Nature Genetics. He received his Ph.D. in genetics while working at Cold Spring Harbor Laboratory. There he developed systems for spatially and temporally controlling the expression of genes in animals and created the first monoclonal antibody against luciferase, which is found in research kits used around the world today. Collections from his field research in Madagascar can be found in four museums including the Smithsonian Museum of Natural History. He is the Chair of the Board for Vivli and the MIT Knowledge Futures Group and serves on the advisory boards for 5 companies.

    Rebecca Lambert
    Founder, CEO, and Executive Chair

    Rebecca Lambert, NED’s Founder and CEO, has over 40 years of experience designing and executing strategies to solve complex issues in business, government, political and financial entities. For the last two decades, Ms. Lambert has led the development of NED’s novel systems treatments for complex disease.

    Ms. Lambert has two patents issued and one pending. The issued patent is for the composition of matter and method of use of a systems cancer treatment. A second patent is for angiogenic regulators and their use in disease diagnosis and treatment. The third patent pending is for the prophylaxis and treatment of upper respiratory viral infections.

    Ms. Lambert’s approach to disease has attracted systems pioneer, Leroy Hood, MD, PhD, (inventor of the DNA synthesizer, enabling technology for the human genome project) who has asked if NED‘s cancer treatment may be used in a large study he plans to show how cancer’s onset may be reversed. NED is collaborating with Dr. Hood and his Institute for Systems Biology in NED’s cancer clinical trial.

    Ms. Lambert’s systems treatment for cancer is unique, prioritizing the most significant drivers of the major processes that advance late-stage cancers (stages II-IV). This treatment combines evidence-based agents already documented as efficacious against key targets at safe non-toxic doses. Her compelling advocacy work with heavily pre-treated late stage IV “observational” cancer patients has been reported to the FDA.

    Lambert’s second oral systems protocol is for respiratory viruses (those known and not yet known) and has the attributes of a “universal” treatment to help better prepare for the next pandemic.

    Prior to founding NED, Ms. Lambert raised over $1B of client funds for Shaker Investments. Previously, she had founded a company that utilized groundbreaking telecommunications technologies to deploy the first compressed digital satellite delivery of multiple TV channels to 40% of U.S. hospitals. She also founded a company to upgrade FM radio properties by moving them into top 100 radio markets.

    Her Federal Government experience includes senior positions in the U.S. House, U.S. Senate, and the Reagan Administration. While Associate Deputy Secretary for the U.S. Department of Commerce during the Reagan Administration, she initiated the Federal Government’s first use of a “Memorandum of Understanding” (MOU) to secure $3B of contracts for U.S. companies to build Brazilian hydro projects. Ms. Lambert also served as Deputy Assistant Secretary of the U.S. Department of Energy. At the Senate, she served as chief of staff for U.S. Senator Malcolm Wallop, and for the Republican Senatorial Committee, Ted Stevens, Chairman.

    Early in her career, Ms. Lambert managed strategy for numerous statewide political campaigns including Senator Malcolm Wallop’s upset victory for the U.S. Senate. She was one of the first non-lawyers to associate with a major Washington, DC law firm, representing Wiley Rein & Fielding clients before the U.S. Congress, White House and other U.S. Departments and Agencies.

    While living in New York City, Ms. Lambert served as the President of Bellevue Hospital’s Bellevue Association Board. During her tenure this organization was revitalized to garner support of Bellevue’s “Heroes Behind the Headlines”– the clinicians, nurses, and allied healthcare workers who routinely care for New York’s police and firefighters, as well as the homeless.

    Ms. Lambert has a BA in political science from Simmons College, and she graduated from Harvard Business School’s Advanced Management Program.

    Carolina Alarco
    Board of Directors

    Carolina Alarco is a dynamic and seasoned biotech executive. She has more than 25 years of experience in the bio

    pharmaceutical industry in Massachusetts. She serves on the Board of two private biotech companies, Syte.bio, Inc. and Dione Antibiotics, Inc. Carolina is the Founder and Principal at Bio Strategy Advisors LLC, a strategic business consulting firm servicing small and medium-sized biotech, medical devices and digital health companies; specializing in start-up company formation, corporate strategy, investment thesis, early round fund-raising, strategic partnerships, commercial planning, go-to-market, product launches and geographical expansion. She is also a Strategic Consultant at Interlink Markets, a boutique investment bank in Boston that facilitates connections between start-ups in the Biotech/Medtech and Tech spaces and strategic partners/investors. Carolina is also a top-tier Founding Venture Partner at AccelHUB Venture Partners, a firm specialized in early seed investing and US soft-landing for Latin American start-ups.

    Carolina has spent more than 25 years in progressive executive leadership roles in Biotech, including 15 years at Genzyme, where she was a Vice-President until the acquisition by Sanofi. At Genzyme, she played a pivotal role in several product launches globally, new market development and geographical expansion. After Genzyme, Carolina went on to be President of  two medium-sized commercial-stage public biotech companies Aegerion Pharmaceuticals and Novelion Therapeutics, until their respective exits.

    Carolina also has a strong philanthropic focus and serves in several non-profit boards. She has currently serves in the Mass General Hospital Board of Trustees (MGPO), the Latino Council at Boston Children’s Hospital, the State of Massachusetts STEM Advisory Council and the Board of Latinos in Bio, of which she is co-Founder and past-Chair. She holds a BS in Business Administration from the University of Lima and a Graduate Degree in Business and Management from Harvard University.

    Fiona Calnan FCCA, FRSA
    Board of Directors

    Fiona Calnan is CEO of Santovia, a healthcare technology company that is working to redefine Health Education and patient engagement.

    Fiona’s first roles and experience were gained in the financial services sector including as Chief Financial Officer at Dresdner Kleinwort Benson responsible globally for corporate finance and equity capital markets. She remained within the financial services sector until 2005 when an unexpected opportunity arose to take a leading role in a healthcare start up.

    UKSH was created in 2005 with no premises or revenue. Starting out as the CFO for the new company, Fiona progressed to CEO in 2007. The first contract was to build, commission and run a  surgical facility exclusively to treat government insured patients that would introduce world-leading evidence-based treatments. This first center was rapidly recognized nationally for the quality of its services and for its wider impact driving improvement in the surrounding healthcare economy. Fiona grew UKSH to a revenue of $100m across five centers. It became the leading privately-owned healthcare company in the UK with a reputation for delivering excellent patient outcomes. It also led the way on transparency of healthcare data through the pioneering publication of its outcome data.

    In 2011 UKSH was named by Dr Foster Intelligence’s assessment of all English hospitals based on government data, as the best hospital in the country for joint replacement surgery.  Fiona was awarded the Best Use of Technology Award 2012 by Laing & Buisson Healthcare and shortlisted for innovation award by the Guardian Newspaper. The organization under her leadership also received awards for excellence in Risk Management and Hospitality. In 2013, UKSH was successfully sold to a competitor.

    Fiona completed two terms as a board member and Chair of the Audit and Governance Committee for the Healthcare Sector Skills Council for the UK, Skills for Health.    Fiona stepped down last year as Chair of the Finance Committee and as a Trustee of The Kiln Theatre in London (previously known as The Tricycle) after serving 10 years on their board.

    Mary Davis
    Board of Directors

    Ms. Mary Graham Davis brings extensive experience in effective organizational structure, business alignment and performance management, senior leadership coaching, and strategic directional change.  Ms. Davis is a senior managing director of Brock Capital Group LLC and founded the Davis Consulting Group LLC in 1996. She retired as the Chair of the Board of Trustees of Mount Holyoke College in 2015.

    Ms. Davis previously served as managing vice president for PeopleTech, where she consulted to U.S. and global organizations implementing change processes resulting from restructuring, high growth opportunities or leadership transitions. Prior to the acquisition by Right, she served as the vice chair of Jannotta, Bray and Associates, head of the Jannotta Consulting Group, and managing director of their New York Metropolitan Area Operating Group. She began her career with CITICORP in the overseas equity investment Edge Act subsidiary.

    Previous board positions include president of the Alumnae Association of Mount Holyoke College, president of the Graham-Windham Services to Families and Children in New York; and member of the Winnetka Public Schools Board of Education.  Ms. Davis has a B.A. from Mount Holyoke College and a master’s degree in international economics from the Fletcher School of La

    Louise Forlenza, CPA
    Board of Directors

    Louise Forlenza is a NY State Licensed CPA and Senior Financial Executive with over 35 years of success assisting domestic and international companies in a diverse range of industries expand their businesses globally. Louise has a proven track record leading privately and publicly held companies from inception to growth and profitability. She is recognized for her complex problem-solving skills, strategic insight, and ability to engage critically important stakeholders to resolve issues and drive transactions to closure. Louise is frequently quoted in Corporate Board Member Magazine and is a financial expert that brings deep experience as Chair of the Audit Committee on corporate boards.

    Since 2002 Louise has been a member of the Board of Innodata Inc. (NADAQ: INOD) where she serves as Chair of the Audit Committee and Nominating Committee. She has served as a Strategic Advisor on the Advisory Committee of NED Biosystems since 2015 and previously served on the Board of the Acting Company as Treasurer and Chair of the Audit Committee.

    Louise founded LC Forlenza Advisory Services in 1987 and continues to preside over the company where she provides strategic insight and expertise in global accounting and reporting, forensic accounting, auditing, foreign tax issues, turnarounds, and litigation support. She has built the business into a thriving practice of over 250 long-tenured reputable global clients in industries such as transportation, entertainment, real estate, life sciences, technology, and health & wellness.

    From 1987 to 1992, Louise served as the COO, Director and Chair of the Audit Committee for Intercontinental Exchange Partners, an $80 million global foreign exchange brokerage firm operating in New York and Dusseldorf. She led operations and administrative support to all non-sales functions for 65 global brokers and 20 administrative staff and rolled out international operations in Dusseldorf. Louise also led the audit and tax relationships with independent audit firms to achieve most favorable tax treatment for worldwide operations and partnership structure.

    In 1981 Louise joined Bierbaum-Martin Inc., a global brokerage firm specializing in foreign exchange, money market transactions, and options. As CFO, Louise managed all non-brokering activities in New York and rolled out international operations in Dusseldorf and London. Additionally, Louise restructured the firm’s capital in London as required by the Bank of England by trading hard assets for cash and increasing liquidity by 50%. She also led the audit and tax relationships with two “Big 8” international audit firms receiving most favorable tax treatment for worldwide operations and structure, supervised the preparation of financial statements for NASD-registered broker dealers acquired in the mergers, and provided infrastructure build-out through three company mergers with an expansion from 10 to 245 brokers.

    Louise received her Bachelor of Business Administration degree in Accounting from Iona College, a Certificate in Forensic Accounting from New York University, is a NY State Licensed CPA, and has completed Executive Training Programs at Harvard Business School and The Wharton School. Louise was the first and only female accounting major to graduate from Iona College in her graduating class.

    Geoffrey Ling, MD, PhD, Col. (Ret.)
    Board of Directors, Scientific Advisory Board

    Dr. Geoffrey Ling is an internationally recognized innovation leader. Dr. Ling is co-founder at On Demand Pharmaceuticals – developing advanced, miniaturized, and automated pharmaceutical manufacturing systems that create from precursors to final formulated drugs. He is Co-Leader of The BrainHealth Project – an initiative to double human brain performance in the next 10 years. He also serves as a Professor of Neurology and is an Attending Neurocritical Care physician at Johns Hopkins University and Hospital and the Uniformed Services University of the Health Science (USUHS). Dr. Ling previously served as the Founding Director of the Biological Technologies Office at the Defense Advanced Research Projects Agency (DARPA) and also Assistant Director for Medical Innovation of the Science Division in President Obama’s White House Office of Science and Technology Policy (OSTP).  He is a retired U.S. Army colonel, who served for 27 years during which time he was deployed to Iraq and Afghanistan.

    Dr. Ling’s medical degree is from Georgetown University and his doctorate in Pharmacology is from Cornell University. He was a postdoctoral research fellow at Memorial Sloan Kettering Cancer Center. His neurology residency was done at Walter Reed Army Medical Center and his Neuro Critical Care fellowship at Johns Hopkins.  He has published over 200 peer-reviewed articles, book chapters and reviews.  He is a member of the honor societies of Alpha Omega Alpha, Sigma Xi and Military Medical Order of Merit. He is a fellow of the American Neurological Association, American Academy of Neurology and Neurocritical Care Society. He is a member of the Society for Critical Care Medicine, American Society of Pharmacology and Experimental Therapeutics and AMSUS (the Society of Federal Health Professionals).

    Josh Kopelman – First Round Capital
    Board Observer

    Forbes 2016 “The Midas List”: #6

    “A staple of the top of the Midas List now in his sixth year in the top 20, Josh Kopelman stands out as a pioneer of a group of top seed-stage investors once called the ‘super angels’ after Kopelman co-founded First Round Capital in 2004.” –Forbes

    Co-Founder, First Round Capital, which has re-invented seed-stage investing with early investments in Blue Apron, Uber, Square, Warby Parker, LinkedIn and NED Biosystems.

    Josh has been an active entrepreneur and investor in the Internet industry since its commercialization.

    Josh co-founded First Round Capital in 2004 to reinvent seed-stage investing. Since that time, the firm has invested in over 300 emerging technology startups – becoming one of the most active venture capital firms in the country. Josh has consistently made the Forbes “Midas List” which ranks the top 100 tech investors, earning the number four spot in 2014. Josh has been named one of the top ten ‘angel investors’ in the United States by Newsweek magazine, one of “Tech’s New Kingmakers” by Business 2.0 magazine and a “Rising VC Star” by Fortune magazine.

    Prior to founding First Round, Josh co-founded three companies: Infonautics Corporation (IPO 1996), Half.com (acquired by eBay in 2000), and TurnTide (acquired by Symantic in 2003). Josh is an inventor on 13 U.S. Patents for his work in Internet technology. In June 2000, he was awarded Ernst and Young’s prestigious “Entrepreneur of the Year” award for the Greater Philadelphia region. Josh earned a Bachelor of Science degree cum laude in Entrepreneurial Management and Marketing from The Wharton School of the University of Pennsylvania.